Title | Effect of lipid composition and pegylation on the interaction of arsonoliposomes with thiols and their in vitro cytotoxicity towards PC3 cells | |
Authors | Paraskevi Zagana¹, Maria Haikou¹, Eleftheria Giannopoulou², Panayiotis V. Ioannou³ and Sophia G. Antimisiaris¹
1. Pharm. Technology Lab, Department of Pharmacy, 2. Pharmacology Lab, School of Medicine and 3. Department of Chemistry, University of Patras, Rio 26510, Greece |
|
Citation | Zagana, P., Haikou, M., Giannopoulou, E., Ioannou, P.V., Antimisiaris, S.G.: Effect of lipid composition and pegylation on the interaction of arsonoliposomes with thiols and their in vitro cytotoxicity towards PC3 cells, Epitheorese Klin. Farmakol. Farmakokinet. 20(2): 352-354 (2006) | |
Publication Date | Accepted for publication: 19-20 May 2006 | |
Full Text Language | English | |
Order – Buy | Ηλεκτρονική Μορφή: pdf (10 €) – Digital Type: pdf (10 €) pharmakonpress[at]pharmakonpress[.]gr | |
Keywords | – | |
Other Terms | review article | |
Summary | Increased toxicity of arsonoliposomes towards cancer cells may imply interaction between arsonolipids and cellular thiols which, would result in reduction of As(V) to the more toxic As(III). For examination of this possibility we investigate the effect of incubating various compositions of arsonoliposomes with glutathione (GSH), on their integrity. If GSH interacts with the As(V) of arsonoliposomes, this may alter their membrane stability. The results of this study show that the effect of glutathione on arsonoliposome integrity is higher when their arsonolipid content increases, indicating that arsonolipid molecules interact with glutathione. In some cases, depending on the rigidity of their membranes, this interaction leads to a destabilization of arsonoliposomes. The destabilizing effect of GSH was higher for PC-based arsonoliposomes compared to DSPC-based ones. For pegylated-arsonoliposomes membrane destabilization was minimal and this may be related to the high stability demonstrated previously for these specific arsonoliposomes, or, it may indicate that pegylation results in prevention (total or partial) of arsonolipid interaction with thiols (perhaps because of steric repulsion). In order to see if PEG-arsonoliposomes are cytotoxic towards cancer cells, we measured by MTT assay, the proliferation of PC3 cells after incubation in presence and absence (control) of different types and amounts of arsonoliposomes. Results show that DSPC- based and pegylated-arsonoliposomes retain toxicity against this cancer cell line. | |
References | 1. Gortzi O., Papadimitriou E., Kontoyannis C., Antimisiaris S.G., Ioannou P.V.: Pharm. Res. 19: 79-86 (2002)2. Gortzi O., Papadimitriou E., Antimisiaris S.G., Ioannou P.V.: Eur. J. Pharm. Sci. 18: 175-183 (2003).3. Dai J., Weinberg R.S., Waxman S., JingY.: Blood 93: 268- 277 (1999)
4. Serves S.V., Sotiropoulos D.N., Ioannou P.V., Jain M.K.:Phosphorous Sulfur Silicon 81: 181-190 (1993) 5. Serves S.V., Tsivgoulis G.M., D Sotiropoulos D.N., Ioannou P.V., Jain M.K.: Phosphorous Sulfur Silicon 71: 99-105 (1992) 6. Piperoudi S., Ioannou P.V., Frederik P., Antimisiaris S.G.: J. Liposome. Res. 15: 187-197 (2005) 7. Piperoudi S., Fatouros D., Ioannou P.V., Frederik P., Antimisiaris S.G.: Chem. Phys. Lipids in press (2006) |
|
Relative Papers |
Online ISSN 1011-6575
Άρθρα Δημοσιευμένα σε αυτό το Περιοδικό Καταχωρούνται στα:
- Chemical Abstracts
- Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Articles published in this Journal are Indexed or Abstracted in: • Chemical Abstracts • Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Συντακτικη Επιτροπή-Editorial Board
ΕΤΗΣΙΑ ΣΥΝΔΡΟΜΗ 2006 – ANNUAL SUBSCRIPTION 2006 | |
Γλώσσα Πλήρους Κειμένου – Full Text Language | Αγγλικά – English |
Παραγγελία – Αγορά – Order – Buy | Ηλεκτρονική Μορφή: pdf (70 €) – Digital Type: pdf (70 €)pharmakonpress[at]pharmakonpress[.]gr |
Έντυπη Μορφή (70 € + έξοδα αποστολής) – Printed Type (70 € + shipping)pharmakonpress[at]pharmakonpress[.]gr |